Key result
Acute MIS-C causes reduced LVEF in ~36% of children, with most recovering by 9 months.
Why the study?
The study aimed to describe the early and up to 16 months follow-up of post-COVID multi-system inflammatory syndrome in children (MIS-C), with special reference to cardiac involvement.
Meta-Analysis (n=4,778)
Yes
OBJECTIVES: We aim to describe the early and upto 16 months follow-up of post-coronavirus disease (COVID), multi-system inflammatory syndrome in children (MIS-C), with special reference to cardiac involvement. STUDY DESIGN: This cohort non-interventional descriptive study included patients <18 years admitted between May, 2020 and April, 2021. Based on underlying similarities, children were classified as post-COVID MIS-C with overlapping Kawasaki Disease, MIS-C with no overlapping Kawasaki Disease, and MIS-C with shock. Post-discharge, patients were followed at 1, 3, 6, 12, and 16 months. RESULTS: Forty-one patients predominantly males (73%), at median age of 7 years (range 0.2-16 years) fulfilled the World Health Organisation criteria for MIS-C. Cardiac involvement was seen in 15 (36.5%); impaired left ventricle (LV) function in 5 (12.2%), coronary artery involvement in 10 (24.4%), pericardial effusion in 6 (14.6%) patients, and no arrhythmias. There were two hospital deaths (4.9%), both in MIS-C shock subgroup (2/10, 20%). At 1 month, there was persistent LV dysfunction in 2/5, coronary artery abnormalities in 7/10, and pericardial effusion resolved completely in all patients. By 6 months, LV function returned to normal in all but coronary abnormalities persisted in two patients. At last follow-up (median 9.8 months, interquartile range 2-16 months), in 36/38 (94.7%) patients, coronary artery dilatation was persistent in 2 (20%) patients. CONCLUSIONS: Children with MIS-C have a good early outcome, though MIS-C with shock can be life-threatening subgroup in a resource-constrained country setting. On midterm follow-up, there is normalisation of LV function in all and recovery of coronary abnormalities in 80% of patients.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a meta-analysis in Multisystem Inflammatory Syndrome in Children (MIS-C) (n=4,778). Multisystem Inflammatory Syndrome in Children (MIS-C) vs. Healthy controls, acute COVID-19, or idiopathic/viral myocarditis (in 7 studies) was evaluated on Pooled frequency of reduced left ventricular ejection fraction (LVEF <55%) in the acute phase (95% CI 31.2-41.6). Children with MIS-C had pooled acute rates of 36.3% for LVEF <55% and 16.1% for coronary abnormalities, with most resolving by 6-9 months and 2.1% retaining coronary abnormalities at 18-24 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: